William Blair Reiterates Outperform Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “outperform” rating restated by stock analysts at William Blair in a research note issued on Wednesday, RTT News reports.

AUTL has been the subject of several other reports. Truist Financial increased their price objective on Autolus Therapeutics from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, August 17th. Deutsche Bank Aktiengesellschaft assumed coverage on Autolus Therapeutics in a report on Thursday, November 9th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $7.00 price target on shares of Autolus Therapeutics in a research report on Wednesday, October 25th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics currently has an average rating of “Buy” and a consensus price target of $8.17.

Autolus Therapeutics Stock Up 2.6 %

NASDAQ AUTL opened at $4.35 on Wednesday. The business has a 50 day moving average price of $2.83 and a 200-day moving average price of $2.80. Autolus Therapeutics has a 52 week low of $1.60 and a 52 week high of $4.39. The company has a market cap of $752.85 million, a price-to-earnings ratio of -4.44 and a beta of 1.52.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AUTL. Perpetual Ltd boosted its stake in Autolus Therapeutics by 7.4% in the second quarter. Perpetual Ltd now owns 1,996,355 shares of the company’s stock worth $4,751,000 after buying an additional 138,264 shares in the last quarter. Boulder Hill Capital Management LP purchased a new stake in Autolus Therapeutics in the first quarter worth about $105,000. B. Riley Wealth Advisors Inc. purchased a new stake in Autolus Therapeutics in the second quarter worth $52,000. Exchange Traded Concepts LLC purchased a new stake in Autolus Therapeutics in the second quarter worth $118,000. Finally, Rathbones Group PLC bought a new position in Autolus Therapeutics in the third quarter worth $171,000. Hedge funds and other institutional investors own 64.78% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.